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Inclusion of Curcumin in β-cyclodextrins as Potential Drug Delivery System: 
Preparation, Characterization and Its Preliminary Cytotoxicity Approaches
(Penambahan Kurkumin dalam β-siklodekstrin sebagai Potensi Sistem Penyampaian Ubat: 
Penyediaan, Pencirian dan Pendekatan Awal Kesitotoksikan)
MUHAMMAD HASNOR JA’FAR, NIK NUR SYAZNI NIK MOHAMED KAMAL, BOON YIH HUI, MUHAMMAD FAHMI 
KAMARUZZAMAN, NUR NADHIRAH MOHAMAD ZAIN, NOORFATIMAH YAHAYA & MUGGUNDHA RAOOV*
ABSTRACT
The development and application of organic based drug carrier in drug delivery system (DDSs) with greater efficacy and 
fewer side effects remains a significant challenge in modern scientific and medical research. The aim of current study 
was to evaluate the ability of β-cyclodextrin (β-CD) as drug delivery carrier to encapsulate Curcumin (CUR), a promising 
chemotherapeutic that exhibits low aqueous solubility and poor bioavailability forming inclusion complex by kneading 
method to enhance its delivery to cancer cells. Different methods and analysis such as Fourier Transform Infrared (FTIR) 
spectrometer, 1H Nuclear Magnetic Resonance (1H NMR), X-Ray Diffraction (XRD), Scanning Electron Microscope (SEM) 
and Thermo-gravimetric Analysis (TGA) were employed to approve the successful formation of the inclusion complex 
where the aromatic ring of CUR has been encapsulated by the hydrophobic cavity of β-CD. UV absorption indicated that 
β-CD complex with CUR with an apparent formation constant of 1.09 × 10-8mol-1dm-3. Based on the data obtained by 
methylthiazole tetrazolium (MTT), β-CD showed that not only did it enhanced Curcumin delivery, but it also improved 
and promoted the anti-proliferative effect of CUR during the complexation rather than CUR alone on the MCF-7 human 
breast cancer cells at 24 h incubation period with IC
50 
lower than that of Curcumin alone. The toxicities of the β-CD-CUR 
towards MCF-7 cells were also compared to the free tamoxifen, Curcumin and β-CD. This study provides a preliminary 
toxicity evaluation based on β-CD-CUR inclusion complex as potential delivery system towards the selected cancer cells.
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ABSTRAK
Perkembangan dan penggunaan pengangkut ubat organik dalam sistem pengangkutan ubat (DDSs) dengan lebih 
berkesan dan kesan sampingan yang sedikit masih menjadi cabaran besar dalam penyelidikan sains dan perubatan 
moden. Objektif kajian ini adalah untuk menilai keupayaan β-siklodekstrin (β-CD) sebagai pengangkut ubat untuk 
merangkumkan Kurkumin (CUR), satu kemoterapeutik yang mempunyai kelarutan air dan ketersediaan biologi rendah 
agar dapat membentuk kompleks inklusi dengan cara menguli untuk meningkatkan penghantarannya ke sel kanser. 
Kaedah pencirian seperti inframerah transformasi Fourier (FTIR), 1H Resonans Magnet Nukleus (1H NMR), pembelauan 
sinar-X (XRD), Mikroskop Elektron Pengimbas (SEM) dan Analisis -Gravimetrik Terma (TGA) telah digunakan untuk 
membuktikan pembentukan kompleks inklusif dengan gelang aromatik CUR telah dirangkumkan dalam rongga hidrofobik 
β-CD. Penyerapan ultra-lembayung (UV) menunjukkan kompleks β-CD dengan CUR mempunyai pembentukan pemalar 
ketara 1.09 × 10-8 mol-1 dm-3. Berdasarkan data methylthiazole tetrazolium (MTT), β-CD bukan sahaja meningkatkan 
pengangkutan Kurkumin  malahan menambah baik dan mempromosikan kesan anti-proliferatifnya semasa kompleks 
pada MCF-7 sel kanser payudara manusia dalam tempoh inkubasi 24 jam dengan IC50 lebih rendah daripada Kurkumin 
sahaja. Toksiksiti β-CD-CUR terhadap sel MCF-7 juga dibandingkan dengan tamoxifen, Kurkumin dan β-CD asli. Kajian ini 
berjaya menyediakan penilaian ketoksikan awal berdasarkan rangkuman kompleks β-CD-CUR sebagai sistem pengangkutan 
ubat yang berpotensi ke arah sel-sel kanser yang dipilih.
Kata kunci: β-siklodekstrin; kesitotoksikan; Kurkumin; rangkuman kompleks 
INTRODUCTION
Nowadays, design and development of high performance 
drug delivery systems (DDSs) have gained great attention 
by government, scientists and pharmaceutical industry. In 
fact, the main purpose of an ideal drug delivery systems is 
to improve the therapeutic efficiency and/or targeted the 
drugs to desire region while simultaneously reducing the 
side effects and increase the desired effects of drugs. The 
naturally derived cytotoxicity agents such as Curcumin 
(Bar-Sela et al. 2010) play potential roles in synergizing 
our current modality of cancer treatments, including 
chemotherapy in cancer treatment. Without a good drug 
delivery carrier, it will cause a poor pharmacokinetic 
profiles and low specificity of these drugs which may affect 
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their therapeutic efficacy (Bar-Sela et al. 2010). Thus, 
choosing an appropriate drug delivery carrier is prior to 
the success of a DDS. 
 Cancer is the leading cause of death worldwide with 
an estimated 84 million casualty between 2005 and 2015 
(Ucar et al. 2017). In conjunction to this, breast cancer is 
the most commonly diagnosed cancer in women around 
the world (Danhier et al. 2010). Changes in reproductive 
factors, environmental exposures, and lifestyle such as 
dietary uptake and physical activity are the major concerns 
contributing to breast cancer. Hence, early detection and 
treatment play a vital role in survival of a patient. However, 
due to low solubility of most cytoxicity drugs caused by 
their hydrophobic nature, their efficacies are described 
to be reduced in the patient’s body (Jabbarzadeh et al. 
2014), thus, higher concentration of chemotherapeutic 
drugs need to be prescribed during treatment. Therefore, 
it is imperative to find an ideal drug delivery carrier in 
reducing the conventional dosage of chemotherapeutic 
drugs without hampering their efficacy in killing those 
cancerous cells. Among the drug delivery carriers that can 
be considered for the drug delivery system (DDS), β-CD 
possesses good potential due to its ability to alter physical, 
chemical and biological properties of guest molecules by 
forming an inclusion complex in both solid and solution 
state, respectively (Memisoglu-Bilensoy et al. 2005). The 
main advantages of natural cyclodextrins as a drug carrier 
include a well-defined chemical structure, allowing space 
for potential sites for chemical modification, availability 
of different cavity sizes from α-, β- and γ-cyclodextrin, 
low toxicity, good pharmacological activity and most 
importantly, its ability to enhance drug solubility in 
aqueous solution and affects the chemical characteristics 
or physicochemical properties of the encapsulated drug. 
Therefore, β-CD is a suitable candidate to transport the 
drugs to their target.
 Curcumin or Curcuma longa (Figure 1), commonly 
known as diferuloyl methane, is a hydrophobic polyphenol 
derived from rhizome (turmeric) of the herb which is 
known to exhibit anti-cancer properties. CUR has been 
widely studied for its potential to protect cardiovascular 
disease and has been utilised in neurodegenerative 
disorders, especially Alzhermer’s and Parkinson’s 
disease (Fermeglia et al. 2003). Besides, CUR also 
possesses properties such as agent for anti-inflammatory, 
antioxidant, immunomodulatory, pro-apoptotic and anti-
angiogenic, as well as chemoprevention agent towards 
colon, pancreatic, cervical cancers and Barrrets mataplasia 
(Wilken et al. 2011). However, CUR has a limited 
pharmaceutical application due to its low water solubility, 
poor bioavailability (Yu & Huang 2010), chemical 
instability and rapid metabolism (Salem et al. 2015) which 
may be corresponding for the pharmacokinetics restriction 
of this molecules (Holder et al. 1978). Therefore, to further 
the clinical application of CUR, the search for an efficient 
and nontoxic carrier for CUR has become more significant. 
Various methods have been applied to enhance Curcumin 
delivery, such as incorporating it into phospholipid 
vesicles (Sou et al. 2008), liposomes (Li et al. 2005)this 
transcription factor is a potential target for the treatment 
of this devastating disease. Curcumin (diferuloylmethane, 
and nanoparticles (Khan et al. 2016). Thus, to address the 
issue related to low solubility of CUR, β-CD is investigated 
on its suitability as a drug carrier in this study. 
FIGURE 1. The chemical structure of CUR
 Although many studies have been carried out with 
β-CD (Wang et al. 2007; Zhang et al. 2015) and Curcumin 
(Gafner et al. 2004; Liu et al. 2013) or both (Mangolim 
et al. 2014); to the best of our knowledge, studies of 
β-CD-CUR inclusion complex focus on its anti-cancer 
activity in particular towards estrogen receptor (ER) 
positive human breast cancer cell line (MCF-7 cells) in 
the scientific literature are scarce and lack reported. 
Based on reviews, Memisoglu-Bilensoy et al. (2005) 
loaded β-CDC6 nanospheres into Tamoxifen citrate 
nanocapsules against MCF-7 cells while Yu and Huang 
(2010) capsulated the Curcumin into polymer micelles 
formed by hydrophobically modified starch and tested on 
human hepatocellular carcinoma cell line HepG2. Both 
studies demonstrated an efficient anti-proliferative effect of 
both cytotoxic agents in the presence of those biopolymers. 
Meanwhile, Jahed et al. (2014) demonstrated the molecular 
modelling for β-CD-CUR complex, however, assessment on 
the cytotoxic activity of this complex was not shown in 
this study. No toxicity study was performed to show the 
anti-proliferative of the complex. Therefore, we believe 
this work may enhance the fundamental value towards the 
supramolecular interaction between β-CD and Curcumin, 
particularly on their anti-proliferative effect in MCF-7 cells. 
Nevertheless, complexation with cyclodextrins is a popular 
combination which may lead to new era for their wide 
applications in different fields to improve the biological 
activities of Curcumin in living systems.
MATERIALS AND METHODS
INSTRUMENTATION
The Nuclear Magnetic Resonance 1H (NMR) spectrum of 
the samples in dimethyl sulfoxide was recorded using Jeol 
JNM-GSX 270 at room temperature. The Fourier Transform 
Infrared (FTIR) spectra were recorded on a Perkin Elmer, 
System 2000 with samples prepared using Attenuated 
Total Reflection (ATR) technique. Scanning Electron 
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Microscope Zeiss Supra 50 VP was used to obtain the 
surface morphology of the host, guest, and host-guest 
inclusion complex (βCD-CUR) at 5000× magnification. 
X-Ray Diffraction (XRD) analysis was analysed using Cu 
Kα irradiation with a Siemens D5000 X-ray diffractometer.
SYNTHESIS OF THE INCLUSION COMPLEX OF 
β-CD AND CURCUMIN
Inclusion complex between βCD with CUR was prepared 
using the kneading method. 0.5 g of βCD and 0.16 g of 
CUR were weighed and kneaded with mortar and pestle 
in minimum ethanol for 20 min to prepare a 1:1 ratio 
complex. The mixture was dried in a desiccator for 48 h 
to constant mass and weighed. The yield percentage for 
βCD-CUR inclusion complex was 79.94%. The powder was 
stored at room temperature.
SPECTROSCOPIC STUDIES
Spectroscopic studies were carried out to determine 
the absorption spectrum, stoichiometry, and formation 
constant of the β-CD-CUR inclusion complex. A UV-Visible 
spectrophotometer with 1 cm quartz cells was used for all 
the following spectroscopic studies. Absorption spectra 
were determined between 300 and 500 nm (Wang et al. 
2007).
EFFECT OF pH
Effect of pH for inclusion complex formation was 
determined by using three different pH buffers. Buffer 
solutions with pH4, pH7 and pH10 have been used to 
determine the optimum pH. Subsequently, the optimum 
pH (pH7) has been used for the absorption spectra and the 
formation constant.
ABSORPTION SPECTRA
Absorption spectra were recorded for βCD, Curcumin and 
inclusion complex with 0.0032 M of βCD and 0.00005 M 
of CUR.
STOICHIOMETRY AND FORMATION CONSTANT
The concentration of β-CD was varied in the range 0-0.005 
M while the concentration of Curcumin was held constant 
at 0.00005 M. The data obtained were used to illustrate 
reciprocal plot for Curcumin–βCD inclusion complex using 
Benesi–Hildebrand equation (Kuntz et al. 1968).
CELL CULTURE AND REAGENTS
Roswell Park Memorial Institute-1640 medium (RPMI-
1640 medium) (Gibco BRL, UK), Fetal Bovine Serum (FBS) 
(Gibco BRL, UK), 10X phosphate buffer saline (Gibco BRL, 
UK), trypsin 0.25% EDTA 0.003% (Gibco BRL, UK) and 
penicillin/streptomycin solution 10 mg/mL (Gibco BRL, 
UK) were used in this study for cell culture and treatment. 
MCF-7 human breast cancer cell line was maintained in a 
humidified 37°C incubator with 5% CO2. All procedures 
were conducted in a class 2 Biohazard Cabinet with a 
proper aseptic technique. Good cell practice guidelines 
were followed throughout the project.
PREPARATION OF INCLUSION COMPLEX FOR TREATMENT
β-CD-CUR inclusion complex were dissolved in 25 mL 
of DMSO and shaken. 0.5 mL of the solution was further 
diluted in 10 mL volumetric flask with RPMI complete 
growth medium and labelled as stock solution. The stock 
was filtered with 0.22 μm sterile nylon filter before further 
dilution with complete growth medium to produce different 
concentrations (50, 100, 150, 200 and 250 μM). 
PREPARATION OF CUR AND Β-CD FOR TREATMENT
1 g of CUR was dissolved in 25 mL DMSO. 0.5 mL of the 
solution was diluted in 10 mL volumetric flask with RPMI 
complete growth medium and labelled as stock solution. 
The stock was filtered with 0.22 μm sterile nylon filter 
before further dilution with complete growth medium to 
produce different concentrations (50, 100, 150, 200 and 
250 μM). 
MTT CELL PROLIFERATION ASSAY
The MTT Cell Proliferation Assay (Merck Millipore, 
Germany) was used to determine the anti-proliferative 
effect of βCD, CUR, βCD-CUR 1:1 complexes on MCF-7 
cell line.
TREATMENT CONTROL
Treatment controls were set up to determine the percentage 
of cell viability after treatment with inclusion complex, 
CUR alone, and β-CD alone. Table 1 shows the positive 
control, negative control, and background control used in 
the experiment.
TABLE 1. The controls used for MTT assay
Type of control Control used
Positive control 50 μM Tamoxifen
Negative control Complete growth medium
(untreated cells)
Background control Blank wells with growth medium 
without cells
TREATMENT OF CELL FOR MTT ASSAY
MCF-7 cells were harvested from the T75 cm2 culture flasks 
using trypsin-EDTA and seeded at 10,000 cells per well in a 
96-well plate. The plate was incubated overnight at 37°C 
with 5% for cells attachment. The culture medium was then 
replaced by assay medium containing treatment with βCD, 
CUR and βCD-CUR 1:1 complex. Positive control, negative 
control, and background control were also included in the 
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assay. All treatments and controls were prepared and loaded 
in triplicates. The plates were incubated for 24 and 48 h.
PREPARATION OF [3(4,5-DIMETHYLTHIAZOL-2YL)-2,5-
DIPHENYLTETRAZOLIUM BROMIDE)] (MTT) SOLUTION
MTT solution was prepared at 5 mg/mL which was 
dissolved in phosphate buffer saline (PBS) and mixed well. 
The solution was filtered using 0.22 μm sterile nylon filter 
and kept at 4°C in the dark.
DETERMINING CELL VIABILITY PERCENTAGE
At each time point, 10 μL of MTT (5 mg/mL) was added to 
each well and the plate was incubated for 4 h at 37°C with 
5% CO2. The medium containing the MTT solution was 
discarded and replaced with 100 μL of DMSO. The optical 
density of each well was read at 570 nm wavelength using 
microplate reader. The percentage of cell proliferation was 
calculated using (1) (Wan Omar et al. 2016):
 % of cell
 proliferation =   (1) 
STATISTICAL ANALYSIS
All data were assayed in three independent experiments. 
The results were displayed as the mean ± standard deviation 
(S.D). Statistical analyses were determined using non-
parametric Independent t-test using IBM SPSS statistics 
version 19 (IBM Inc., USA) since the sample size was <30.
RESULTS AND DISCUSSION
CHARACTERIZATION
Fourier Transform Infrared (FTIR) Analysis  FTIR is a 
useful tool to confirm the formation of a host-guest 
inclusion complex. The spectrum of the inclusion 
complex looks almost similar to the pure βCD indicating 
a formation of an inclusion complex as demonstrated 
in Figure 2. The FTIR spectrum of CUR exhibited an 
absorption band at 3510 cm-1 indicating the presence 
of phenolic stretching vibration. Furthermore, a sharp 
absorption at 1602 cm-1 (stretching vibration of the CUR 
benzene ring), 1507 cm-1 (vibration of C=O and C=C of 
CUR), 1429 cm-1 (Coolefinic C-H bending vibration), 1275 
cm-1 (aromatic C-O stretching vibrations) and 1026/857 
cm-1 (C-O-C stretching vibration of CUR) confirms the 
presence of the functional groups in CUR. 
 The FTIR spectra of β-CD show characteristic peaks at 
3333 and 2922 cm-1 caused by the O-H and C-H stretching 
of vibration. Besides that, peaks at 1653, 1276, 1025 and 
858 cm-1 indicates the presence of HOH, C-O, C-O-C 
stretching glucose units and C-O-C of rings of β-CD. In 
the case of inclusion complex between β-CD and CUR, all 
the sharp peaks belonging to the β-CD exist and only a 
few characteristics of CUR peaks are visible. The shifts to 
all β-CD related peaks were shifted to a higher or lower 
wavelength such as at 3333 to 3336 cm-1, 1653 to 1627 
cm-1 and 858 to 857 cm-1. The broader OH stretching band 
of the inclusion complex in the frequency 3336 cm-1 again 
corresponds to the multiple OH functional groups of β-CD 
molecules (Subramaniam et al. 2010; Williams III et al. 
1998). Therefore, these data confirm the presence of CUR 
and β-CD in the βCD-CUR inclusion complex.
 Table 2 shows the differences in frequencies between 
β-CD and their inclusion complex measured in intensity 
changes δ). The increment was due to the insertion of 
benzene ring from CUR into the electron rich cavity 
of β-CD, which increases the density of electron cloud 
and causes frequency to increase. Whereas, decline in 
frequency between the inclusion complex and CUR (Table 
3) is caused by the changes in the microenvironment that 
leads to the formation of hydrogen bonding and van der 
Waals forces in their interaction during the complexation 
(Jahed et al. 2014). Thus, the FTIR spectra prove the 
formation of the βCD-CUR inclusion complex.
X-RAY DIFFRACTION (X-RD) ANALYSIS
X-ray diffraction (XRD) provides further confirmation for 
the formation of an inclusion complex and it is commonly 
used to determine the formation of a new compound from 
FIGURE 2. FTIR spectra of (a) β-CD, (b) CUR, and (c) β-CD-CUR inclusion complex
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their original molecules (Zhang et al. 2015). The X-ray 
diffractogram of CUR and β-CD exhibited sharp, thin and 
intense peak which showed their characteristic crystalline 
peaks. This is in accordance with previous reports of CD 
inclusion complexes (Mangolim et al. 2014; Yallapu et al. 
2010). β-CD has a major peak at 2θ= 9.5°, 11.1° and 12.8° 
while CUR has a characteristic peak at 2θ= 8.9°,14.8° and 
19.6°. In the formation of inclusion complex, the peaks at 
2θ= 9.5°, 11.1° and 12.8° of βCD decreased in intensity 
and sharpness (Figure 3). Besides that, characteristic 
peaks of CUR at 2θ= 8.9°, 14.8° and 19.6° also lost 
their intensity and broadening. The loss of intensity and 
increase in peak broadness indicate reduction in degree 
of crystallinity in the inclusion complex (Mangolim 
et al. 2014). This reduction showed that the complex 
may be converted from the crystalline into the slightly 
amorphous form, thereby increasing the rate of CUR 
dissolution (Rachmawati et al. 2013). Therefore, the 
formation of an inclusion compound between β-CD and 
CUR was confirmed.
1H NUCLEAR MAGNETIC RESONANCE (NMR) 
SPECTRA ANALYSIS
1H NMR is a useful tool to confirm the formation of an 
inclusion complex and to provide useful information on 
the inclusion mechanism of β-cyclodexrin and the guest 
molecule (Mohamad et al. 2011). The NMR spectrum of 
the inclusion complex and their parent molecules can be 
observed in Figure 4.
 The chemical shifts between β-CD and the inclusion 
complex can be seen in Table 4. The data showed that 
the most obvious chemical shifts occurred at H-3 and 
H-5 which are located inside the cavity of the β-CD. The 
spectrum of β-CD-CUR inclusion complex indicated a shift 
in H-3 from 3.643 ppm to 3.790 ppm (shifted by +0.147 
ppm) and H-5 from 3.606 ppm to 3.679 ppm (shifted by 
+0.073 ppm). The shifts in H-3 and H-5 were bigger than 
H-1 (+0.002 ppm), H-2 (-0.040 ppm), H-4 (+0.004 ppm), 
and H-6 (-0.012 ppm). Thus, the shifts in H-3 and H-5 
located inside the cavity of β-CD confirm the formation of 
an inclusion complex (Jahed et al. 2014). Other than that, 
TABLE 3. Comparison between the intensity of CUR and the inclusion complex of β-CD-CUR
Functional Group Wavenumber (cm-1) Changes
δCUR Inclusion complex
[OH] 3510 3336 -174
TABLE 2. Comparison between the intensity of β-CD and the inclusion complex of β-CD-CUR
Functional Group Wavenumber (cm-1) Changes
δβ-CD Inclusion complex
[OH] symmetric and anti-symmetric
[CH]
[C-O-C]
3333
2922
1025
3336
2923
1026
+3
+1
+1
FIGURE 3. X-ray diffractogram of (a) β-CD, (b) CUR, and (c) βCD-CUR inclusion complex
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FIGURE 4. NMR spectrum of (a) β-CD, (b) CUR, and (c) βCD-CUR inclusion complex
(c)
(b)
(a)
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the slight marginal shift of protons H-2 and H-4 suggests 
CUR as an interaction only with the internal hole of β-CD 
and it is not involved in solubility enhancement of CUR 
(Jahed et al. 2014). The same phenomenon is observed 
in H-1 and H-6. Spectrum shifts for CUR to inclusion 
complex can be observed in Table 3.3. For the spectrum 
of a symmetrical compound, two carbons will have 
similar peaks. For example, in CUR, both Ha and Hg will 
have a peak at 7.526 ppm. The spectrum belonging to the 
aromatic ring in CUR shows the most significant shifts at 
Hi (+0.118 ppm) and Hj (+0.070 ppm), suggesting that 
the aromatic group of CUR reacted with the inner cavity of 
β-CD. Moreover, the presence of 1H signal from both CUR 
and β-CD in the β-CD-CUR 1H NMR spectrum indicates the 
formation of a new inclusion complex. 
CORRELATION SPECTROSCOPY (COSY) ANALYSIS
2D 1H-1H COSY spectroscopic technique was studied which 
is a powerful technique to investigate the intermolecular 
interaction and confirm the formation of the inclusion 
complex (Raoov et al. 2013). Besides that, 2D NMR enables 
us to determine the interaction between the guest and the 
host molecules in the complexes and the connectivity 
between their neighbouring protons in the cavity of the 
inclusion complex (Gómez-Galván et al. 2016). The 1H 
NMR results showed the presence of a guest molecule 
inside the cavity of β-CD and can be confirmed by 2D 
COSY (Mohamad et al. 2011). The cross-peak in Figure 5 
originates from the interaction of protons of β-CD and CUR. 
The cross peak at 3.679-3.790 ppm which belongs to β-CD 
(H-3 and H-5) and the aromatic region of CUR at 5.82 ppm 
TABLE 4. Chemical shifts (δ) of β-CD, CUR and β-CD-CUR inclusion complex
β-CD CUR β-CD-CUR
Δδ  (ppm) Δδ (ppm) Δδ (ppm) Δδ (ppm)
H1
H2
H3
H4
H5
H6
Ha
Hd
Hg
Hh
Hi
Hj
Hk
Hl
4.786
3.629
3.643
3.566
3.606
4.443
7.526
6.000
7.526
6.793
7.121
5.750
3.795
7.282
4.788
3.589
3.790
3.570
3.679
4.431
7.533
6.002
7.533
6.786
7.239
5.820
3.790
7.273
+0.002
-0.040
+0.147
+0.004
+0.073
-0.012
+0.007
+0.002
+0.007
-0.007
+0.118
+0.070
-0.005
-0.009
Values in bold refer to the highest chemical shift of that particular proton
FIGURE 5. The correlation spectra of βCD-CUR inclusion complex in DMSO
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demonstrates strong intensity. Therefore, we can conclude 
that the aromatic ring of CUR has entered the cavity of β-CD.
SCANNING ELECTRON MICROSCOPE (SEM) ANALYSIS
SEM studies were conducted to investigate the morphology 
of β-CD, CUR and βCD-CUR inclusion complex (Figure 6). 
SEM pictures showed that β-CD has a crystalline flake-like 
structure throughout the sample. CUR on the other hand 
shows a highly rod-like spherical crystals. However, 
the β-CD-CUR inclusion complex does not show neither 
crystalline flakes nor spherical-crystals. Instead, the βCD-
CUR inclusion complex exhibits a combination of large 
and small irregular-shaped clumps. The morphological 
change from flake-like structure to smaller aggregates 
is due to CUR encapsulation in the cavities of β-CD. The 
morphology obtained was in a good agreement with few 
studies (Rachmawati et al. 2013; Yallapu et al. 2010).
THERMOGRAVIMETRIC ANALYSIS (TGA) ANALYSIS
TGA is a frequently used technique for measuring a 
compound’s thermal stability in which TGA will be done 
on samples to identify the changes in weight percent with 
respect to temperature change (Sambasevam et al. 2013)1H 
Nuclear Magnetic Resonance (1H NMR. In this study, the 
thermal stability of βCD-CUR was evaluated using TGA 
and the results were compared with pure β-CD and free 
Curcumin. Figure 7 shows the weight loss curves for β-CD-
CUR and its precursors in the temperature range of 0-800°C. 
βCD started to decompose at 320°C. Visible changes 
occurred at 120°C due to the endothermic behaviour which 
corresponded to the loss of water molecules in βCD cavity. 
Meanwhile, Curcumin exhibited weight losses at 240°C 
and 450°C which were due to the degradation of benzyl 
part. Then the inclusion complex underwent weight losses 
in three stages and lost 95% of its original weight at 730°C. 
The first stage is due to the dehydration of water molecules 
while the second stage is due to decomposition of β-CD 
and the third stage is probably due to the decomposition 
of Curcumin. The degradation and weight loss steps of the 
samples are shown in Table 5.
SPECTROSCOPIC STUDIES
Effect of pH   The effect of pH (pH 4, 7 and 10) has been 
studied in order to determine the optimum pH of inclusion 
TABLE 5. Thermo gravimetric analysis result of samples
Sample Region (°C) Weight loss (%) Assignment
β-CD 120
320-480
11.0
85.0
Water loss
β-CD
Curcumin 240
450
3.00
50.0
Benzyl
C=O
β-CD-CUR 110
320
730
9.00
18.0
95.0
Water loss
β-CD
Curcumin
FIGURE 6. The Scanning Electron Microscope photographs of (a) β-CD, (b) CUR, 
(c) β-CD- CUR inclusion complex observed under 5000× magnification
(c)
(a) (b)
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formation between β-CD and Curcumin. No absorbance 
was observed for pH10 (as shown in Figure 8). pH7 
(at 426 nm) was chosen to be the optimum pH rather 
than pH4 for this inclusion complex due to the ease of 
experimental preparation. This is a phenomena where at 
pH7, Curcumin is weak and less stable (Jha et al. 2016) 
and able to form highly stable inclusion complex with 
β-CD. Besides that, neutral forms of Curcumin are also 
predominant at neutral pH which ease the formation of 
inclusion complex.
9. Based on the result, the increase on the absorbance 
intensity of the complex was due the formation of the 
inclusion complex with the β-CD. This can be proven 
by the fact that increase and shift on the intensities were 
rationalized act as the indicator of inclusion complex 
formation (Wang et al. 2007). The influence of β-CD 
concentration on CUR was also studied. As can be seen in 
Figure 3.9, the addition of β-CD had caused a noticeable 
increase in the absorption intensity. This is due to the 
structure of Curcumin that contains two aromatic ring 
systems possessing o-methoxy phenolic groups which 
can be included by β-CD cavity molecule. Upon inclusion 
in the β-CD cavity, generally the absorbance of the guest 
molecule will be enhanced due to the shielding of the 
excited species from no-radiative processes occurring 
in the bulk solution and also due to the increase in molar 
absorption coefficient of the inclusion complex (β-CD-
CUR) (Mohamad et al. 2011). 
FIGURE 7. TGA curves of (a) β-CD; (b) Curcumin; 
(c) β-CD-CUR
FIGURE 8. The effect of pH on absorption spectra of (a) pH7; 
(b) pH4 and (c) pH10
ABSORPTION SPECTRA
Absorption spectra were used to confirm the formation of 
inclusion complex. The absorption spectra of β-CD-CUR 
complex, CUR and β-CD were recorded with accordance to 
procedure in Section Spectroscopic Studies. The obtained 
result showed that β-CD had no absorption in the range 
of 300-500 nm. While CUR had a maximum absorption 
wavelength at 419 nm, the absorbance of β-CD-CUR was 
higher than that of CUR at 426 nm as shown in Figure 
FIGURE 9. The absorption spectra of (a) β-CD-CUR inclusion 
complex, (b) CUR, and (c) β-CD at pH 7 with [β-CD]: 0.0032M 
and [CUR]: 0.00005M at 
max
 = 426 nm
FIGURE 10. Absorption spectra of [CUR] = 0.00005M with various 
concentrations of β-CD at pH 7. From lines 0 to 5: 0 M; 0.001M; 
0.002 M; 0.003 M; 0.004 M; 0.005 M at 
max
 = 426 nm
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STOICHIOMETRY OF THE COMPLEX AND 
FORMATION CONSTANT
The formation constant is the most important parameter in 
the study of inclusion behaviour of β-CD. The formation 
constant for the inclusion complex has been determined 
by analysing the changes in the intensities of absorption 
with different concentrations. The formation constant 
was denoted and the stoichiometric ratio of the β-CD-
CUR was determined using modified Benesi-Hildebrand 
equation (Wang et al. 2007). The K value was calculated 
by dividing the slope with the intercept of straight line 
obtained from the double reciprocal plot. The apparent 
formation constant was determined to be 1.093 × 10-8 
mol-1 dm-3. Hence, we propose that the CUR ideally tends 
to form inclusion complex in 2:1 ratio due to the presence 
of two aromatic rings and this can be proved (Wang et 
al. 2007) by the good linear relationship obtained when 
is plotted against with R2 = 0.9943 for β-CD-CUR (Figure 
11), indicating that the stoichiometric ratio of the complex 
formed should be 2:1. 
increased, where CUR at the highest concentration (250 
µM) led to only 30.4% of growth inhibition in MCF-7 
cells. Importantly, anti-proliferative effect of CUR was 
potentiated by the presence of the β-CD. The percentage of 
cell death was increased from 61.75% to 73.07% in MCF-7 
cells treated with β-CD-CUR inclusion complex in which 
150 µM concentration of the complex caused the greatest 
cell inhibition. This shows a trend that percentages of cell 
death decreased with increasing of β-CD-CUR concentration. 
At 48 h of incubation period, CUR alone (curve a) inhibited 
the growth of MCF-7 cells in a dose-dependent manner, in 
which the maximum anti-proliferative effect was obtained 
at concentration of 200 µM, with 95.1% of cell death. β-CD-
CUR complex at 250 µM concentration inhibited 90.65% 
growth of MCF-7 cells. Within 48 h incubation period, the 
percentage of cell death increased proportionally with the 
increasing concentration of β-CD-CUR inclusion complex. 
CUR alone needs longer incubation period (48 h) to show 
its anti-proliferative efficacy in killing MCF-7 cancerous 
cells, whilst β-CD co-treatment shortens the time exposure 
for CUR to induce cytotoxic of MCF-7 cells within 24 h of 
incubation period. These data also demonstrate that β-CD-
CUR inclusion complex potently inhibited the MCF-7 cells 
greater than CUR alone, particularly at 24 h post-treatment 
at all concentrations tested in this study. The addition of 
β-CD has potentiated and enhanced the water solubility of 
CUR probably accounts for the favourable effect (Jahed et 
al. 2014), thus speeding up their efficacy to prevent the 
growth of MCF-7 cells compared to the treatment of CUR 
alone. This suggests that β-CD delivery is more efficient 
for curcumin and is therefore a preferred vehicle or a drug 
carrier. 
 Figure 14 shows the anti-proliferative effects for all 
treatments, including negative control (untreated cells), 
positive control (tamoxifen-treated cells), CUR alone, β-CD 
alone, as well as β-CD-CUR inclusion complex at both 24 
h and 48 h, respectively. At 24 h of incubation period, the 
percentage of cell viability reached 103. % at 50 µM of 
β-CD, whilst showing a decrease to 29.63% in 150 µM of 
β-CD-treated cells. Nonetheless, the highest concentration 
of β-CD alone only caused little cytotoxicity (less than 
10% of cell death) at 48 h incubation period. β-CD-CUR 
inclusion complex potently decreased the proliferation of 
MCF-7 cells, where only 27% and 9% of viable cells were 
FIGURE11. Reciprocal plot for 1/A against 1/[β-CD]2 of ideal 
β-CD-CUR inclusion complex
INCLUSION STRUCTURE
The possible inclusion mechanism was proposed from 
the stoichiometric ratio 2:1 as predicted using Benesi-
Hildebrand equation. This is the same finding proposed 
by Jahed et al. (2014) in which from the result of NMR, it 
was observed that β-CD interacts with CUR in 2:1 ratio. It 
also shows that in a stable complex, two aromatic rings of 
CUR interact with two β-CDs through the hydrogen bonds 
as shown in Figure 12.
ANTI-PROLIFERATIVE STUDIES
Figure 13 shows the comparison of anti-proliferative 
effects of β-CD-CUR inclusion complex versus CUR alone 
at 24 h and 48 h of incubation periods, respectively. At 24 
h time point, the percentage of cell death for CUR (curve a) 
treated cells range from 30.4-64.8 %. The data showed that 
100 mM of CUR alone inhibited the highest cell proliferation 
of MCF-7 cells, which is at 64.8%. However, the percentage 
of cell death decreased when the concentration of CUR 
FIGURE 12. Proposed inclusion structure of β-CD-CUR in 
ratio 2:1
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observed at 24 h and 48 h post-treatment, respectively. 
Overall, β-CD-CUR inclusion complex shows a significant 
anti-proliferative effect with more than 70 % of cell death 
obtained at all concentrations tested in this study. 
 Data shown are the mean values ± S.D. for three 
independent experiments. Statistical analyses were 
determined using Independent t test with ap<0.05, bp<0.01, 
cp<0.001, significantly different to control (untreated 
sample) and *p<0.05, β-CD-CUR compared to CUR alone
CONCLUSION
In this study, we have demonstrated the feasibility of β-CD 
to encapsulate Curcumin via inclusion complexation by 
using kneading technique. Our study shows that Curcumin 
was efficiently encapsulated into the cavity of β-CD and 
the formation of the inclusion complex was confirmed in 
the characterization part using FTIR, SEM, TGA, 1H NMR and 
XRD. The chemical shifts in each characterization showed 
pattern or characteristics from their parent molecule in the 
inclusion complex with slight shifts and differences. Based 
on the anti-proliferative study, we can conclude that the 
β-CD is a potential bioorganic drug delivery carrier since it 
has shown to be effective in inhibiting the growth of MCF-7 
cells by not only increasing the solubility and enhancing 
Curcumin delivery while promoting and improving the 
anti-proliferative effect of CUR during the complexation 
rather than CUR alone at 24 h incubation period. Our study 
brings the idea to support the use of β-CDs as a key tool to 
improve the pharmaceutical and pharmacological aspects 
of Curcumin for turning these widely available natural 
products into effective drugs.
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